Skip to main content
Article
Licensed
Unlicensed Requires Authentication

Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue

  • , , , and EMAIL logo
Published/Copyright: January 10, 2015
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Clinical Chemistry and Laboratory Medicine (CCLM) Volume 53 Issue 7

Abstract

Background: MicroRNAs (miRNAs) have shown to be promising novel biomarkers in various cancers. We aimed to translate the results of an own previous tissue-based miRNA profile of prostate carcinoma (PCa) with upregulated miR-183 and downregulated miR-205 into a urine-based testing procedure for diagnosis of PCa.

Methods: Urine sediments were prepared from urine samples collected after a standardized digital-rectal examination (DRE) of patients undergoing prostate biopsy with PSA (prostate-specific antigen) values <20 μg/L in consecutive order. According to the sample-size calculation (α=0.05, power=0.95), 38 patients each with PCa and without PCa were randomly enrolled in this study. PCA3 (prostate cancer associated 3) in urine as Food and Drug Administration-approved assay was determined as reference standard for comparison. The miRNAs were measured by RT-qPCR using TaqMan assays and normalized using different approaches.

Results: Both miRNAs were correlated to the mRNA PSA concentrations in the sediments indicating a relationship to the released prostate cells after DRE. However, they had no discriminating capacity between patients with and without PCa. In contrast, PCA3 clearly differentiated between these two patients groups. There was also no significant correlation between miRNAs and standard clinicopathologic variables like Gleason score and serum PSA.

Conclusions: The data of our study show that miR-183 and miR-205 failed to detect early and aggressive PCa despite their highly dysregulated expression in cancer tissue. Our results and the critical evaluation of the few data of other studies raise serious doubts concerning the capability of urinary miRNAs to replace or improve PCA3 as predictive marker for prostate biopsy outcome.

Keywords: diagnostic validity; microRNAs; PCA3; prostate carcinoma; urine sediment
Corresponding author: Klaus Jung, Department of Urology, University Hospital Charité and Berlin Institute for Urologic Research, Schumannstr. 20/21, 10117 Berlin, Germany, Phone: +49-30-450-515041, E-mail:

References

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9–29.10.3322/caac.21208Search in Google Scholar

2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer. Available from: http://globocan.iarc.fr. Accessed on 6 October, 2014.Search in Google Scholar

3. Wilt TJ, Scardino PT, Carlsson SV, Basch E. Prostate-specific antigen screening in prostate cancer: perspectives on the evidence. J Natl Cancer Inst 2014;106:dju010.10.1093/jnci/dju010Search in Google Scholar

4. Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol 2014;65:1046–55.10.1016/j.eururo.2013.12.062Search in Google Scholar

5. Bunting PS. Screening for prostate cancer with prostate-specific antigen: beware the biases. Clin Chim Acta 2002;315:71–97.10.1016/S0009-8981(01)00717-3Search in Google Scholar

6. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320–8.10.1056/NEJMoa0810084Search in Google Scholar PubMed

7. Grubb RL III, Pinsky PF, Greenlee RT, Izmirlian G, Miller AB, Hickey TP, et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. Br J Urol Int 2008;102:1524–30.10.1111/j.1464-410X.2008.08214.xSearch in Google Scholar PubMed

8. Gulati R, Inoue LY, Gore JL, Katcher J, Etzioni R. Individualized estimates of overdiagnosis in screen-detected prostate cancer. J Natl Cancer Inst 2014;106:djt367.10.1093/jnci/djt367Search in Google Scholar PubMed PubMed Central

9. Stephan C, Ralla B, Jung K. Prostate-specific antigen and other serum and urine markers in prostate cancer. Biochim Biophys Acta 2014;1846:99–112.10.1016/j.bbcan.2014.04.001Search in Google Scholar PubMed

10. Ralla B, Stephan C, Meller S, Dietrich D, Kristiansen G, Jung K. Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies. Crit Rev Clin Lab Sci 2014;51:200–31.10.3109/10408363.2014.914888Search in Google Scholar PubMed

11. Kelly BD, Miller N, Healy NA, Walsh K, Kerin MJ. A review of expression profiling of circulating microRNAs in men with prostate cancer. Br J Urol Int 2013;111:17–21.10.1111/j.1464-410X.2012.11244.xSearch in Google Scholar PubMed

12. Mlcochova H, Hezova R, Stanik M, Slaby O. Urine microRNAs as potential noninvasive biomarkers in urologic cancers. Urol Oncol 2014;32:41–9.10.1016/j.urolonc.2013.04.011Search in Google Scholar PubMed

13. Kuner R, Brase JC, Sultmann H, Wuttig D. microRNA biomarkers in body fluids of prostate cancer patients. Methods 2013;59:132–7.10.1016/j.ymeth.2012.05.004Search in Google Scholar PubMed

14. Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 2012;106:768–74.10.1038/bjc.2011.595Search in Google Scholar PubMed PubMed Central

15. Casanova-Salas I, Rubio-Briones J, Calatrava A, Mancarella C, Masia E, Casanova J, et al. Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy. J Urol 2014;192:252–9.10.1016/j.juro.2014.01.107Search in Google Scholar PubMed

16. Haj-Ahmad TA, Abdalla MA, Haj-Ahmad Y. Potential urinary miRNA biomarker candidates for the accurate detection of prostate cancer among benign prostatic hyperplasia patients. J Cancer 2014;5:182–91.10.7150/jca.6799Search in Google Scholar PubMed PubMed Central

17. Srivastava A, Goldberger H, Dimtchev A, Ramalinga M, Chijioke J, Marian C, et al. MicroRNA profiling in prostate cancer – the diagnostic potential of urinary miR-205 and miR-214. PLoS One 2013;8:e76994.10.1371/journal.pone.0076994Search in Google Scholar PubMed PubMed Central

18. Leyten GH, Hessels D, Jannink SA, Smit FP, de JH, Cornel EB, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol 2014;65:534–42.10.1016/j.eururo.2012.11.014Search in Google Scholar PubMed

19. Dijkstra S, Mulders PF, Schalken JA. Clinical use of novel urine and blood based prostate cancer biomarkers: a review. Clin Biochem 2014;47:889–96.10.1016/j.clinbiochem.2013.10.023Search in Google Scholar PubMed

20. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem 2003;49:1–6.10.1373/49.1.1Search in Google Scholar PubMed

21. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006;52:1089–95.10.1373/clinchem.2005.063289Search in Google Scholar PubMed

22. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 2010;126:1166–76.10.1002/ijc.24827Search in Google Scholar

23. Stephan C, Jung K, Semjonow A, Schulze-Forster K, Cammann H, Hu X, et al. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [–2]proprostate-specific antigen-based prostate health index for detection of prostate cancer. Clin Chem 2013;59:280–8.10.1373/clinchem.2012.195560Search in Google Scholar PubMed

24. Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008;179:1587–92.10.1016/j.juro.2007.11.038Search in Google Scholar PubMed

25. Wotschofsky Z, Liep J, Meyer H-A, Jung M, Wagner I, Disch AC, et al. Identification of metastamirs as metastasis-associated microRNAs in clear cell renal cell carcinomas. Int J Biol Sci 2012;8:1363–74.10.7150/ijbs.5106Search in Google Scholar PubMed PubMed Central

26. Jung M, Schaefer A, Steiner I, Kempkensteffen C, Stephan C, Erbersdobler A, et al. Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. Clin Chem 2010;56:998–1006.10.1373/clinchem.2009.141580Search in Google Scholar PubMed

27. Schaefer A, Jung M, Miller K, Lein M, Kristiansen G, Erbersdobler A, et al. Suitable reference genes for relative quantification of miRNA expression in prostate cancer. Exp Mol Med 2010;42:749–58.10.3858/emm.2010.42.11.076Search in Google Scholar PubMed PubMed Central

28. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009;55:611–22.10.1373/clinchem.2008.112797Search in Google Scholar PubMed

29. Tao Z, Shen M, Zheng Y, Mao X, Chen Z, Yin Y, et al. PCA3 gene expression in prostate cancer tissue in a Chinese population: quantification by real-time FQ-RT-PCR based on exon 3 of PCA3. Exp Mol Pathol 2010;89:58–62.10.1016/j.yexmp.2010.01.008Search in Google Scholar PubMed

30. Bu H, Bormann S, Schafer G, Horninger W, Massoner P, Neeb A, et al. The anterior gradient 2 (AGR2) gene is overexpressed in prostate cancer and may be useful as a urine sediment marker for prostate cancer detection. Prostate 2011;71:575–87.10.1002/pros.21273Search in Google Scholar PubMed

31. Jansen FH, van Schaik RH, Kurstjens J, Horninger W, Klocker H, Bektic J, et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010;57:921–7.10.1016/j.eururo.2010.02.003Search in Google Scholar PubMed

32. Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, part I. J Clin Chem Clin Biochem 1983;21:709–20.10.1515/cclm.1983.21.11.709Search in Google Scholar

33. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837–45.10.2307/2531595Search in Google Scholar

34. Filella X, Gimenez N. Evaluation of [–2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clin Chem Lab Med 2013;51:729–39.10.1515/cclm-2012-0410Search in Google Scholar PubMed

35. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93:1054–61.10.1093/jnci/93.14.1054Search in Google Scholar PubMed

36. Bustin SA. Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. J Mol Endocrinol 2002;29:23–39.10.1677/jme.0.0290023Search in Google Scholar PubMed

37. Kirschner MB, van ZN, Reid G. Cell-free microRNAs: potential biomarkers in need of standardized reporting. Front Genet 2013;4:56.10.3389/fgene.2013.00056Search in Google Scholar PubMed PubMed Central

38. Lam B, Simkin M, Rgheil N, Haj-Ahmad Y. Revised guidelines for RNA quality assessment for diverse biological sample input. Application Note 2012;47:1–4.Search in Google Scholar

39. Sapre N, Hong MK, Macintyre G, Lewis H, Kowalczyk A, Costello AJ, et al. Curated microRNAs in urine and blood fail to validate as predictive biomarkers for high-risk prostate cancer. PLoS One 2014;9:e91729.10.1371/journal.pone.0091729Search in Google Scholar PubMed PubMed Central

40. Ohl F, Jung M, Xu C, Stephan C, Rabien A, Burkhardt M, et al. Gene expression studies in prostate cancer tissue: which reference gene should be selected? J Mol Med 2005;83: 1014–24.10.1007/s00109-005-0703-zSearch in Google Scholar PubMed

41. Kattan MW. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 2003;95:634–5.10.1093/jnci/95.9.634Search in Google Scholar PubMed

42. Elkin EB, Vickers AJ, Kattan MW. Primer: using decision analysis to improve clinical decision making in urology. Nat Clin Pract Urol 2006;3:439–48.10.1038/ncpuro0556Search in Google Scholar PubMed

43. Hessvik NP, Phuyal S, Brech A, Sandvig K, Llorente A. Profiling of microRNAs in exosomes released from PC-3 prostate cancer cells. Biochim Biophys Acta 2012;1819:1154–63.10.1016/j.bbagrm.2012.08.016Search in Google Scholar PubMed

44. Schaefer A, Stephan C, Busch J, Yousef GM, Jung K. Diagnostic, prognostic, and therapeutic implications of miRNAs in urologic tumors. Nat Rev Urol 2010;7:286–97.10.1038/nrurol.2010.45Search in Google Scholar PubMed

45. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8–15.10.1016/S0302-2838(03)00201-XSearch in Google Scholar

Supplemental Material

The online version of this article (DOI: 10.1515/cclm-2014-1000) offers supplementary material, available to authorized users.

Received: 2014-10-10
Accepted: 2014-11-30
Published Online: 2015-1-10
Published in Print: 2015-6-1

©2015 by De Gruyter

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Personalized medicine: moving from simple theory to daily practice
  4. Evaluating and using innovative technologies: a lesson from Theranos?
  5. Review
  6. Emerging biomarkers in the detection and prognosis of prostate cancer
  7. Mini Review
  8. Could molecular assessment of calcium metabolism be a useful tool to early screen patients at risk for pre-eclampsia complicated pregnancy? Proposal and rationale
  9. Opinion Papers
  10. Is laboratory medicine ready for the era of personalized medicine? A survey addressed to laboratory directors of hospitals/academic schools of medicine in Europe
  11. Theranos phenomenon: promises and fallacies
  12. Clinical laboratories: production industry or medical services?
  13. Genetics and Molecular Diagnostics
  14. Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms
  15. Direct identification of Gram-positive bacteria and resistance determinants from blood cultures using a microarray-based nucleic acid assay: in-depth analysis of microarray data for undetermined results
  16. General Clinical Chemistry and Laboratory Medicine
  17. Comparison between bottom-up and top-down approaches in the estimation of measurement uncertainty
  18. Role of vitamin D and sFlt-1/PlGF ratio in the development of early- and late-onset preeclampsia
  19. Adenosine deaminase, dipeptidyl peptidase-IV activities and lipid peroxidation are increased in the saliva of obese young adult
  20. PON-1 and ferroxidase activities in older patients with mild cognitive impairment, late onset Alzheimer’s disease or vascular dementia
  21. Comparison of five automated hematology analyzers in a university hospital setting: Abbott Cell-Dyn Sapphire, Beckman Coulter DxH 800, Siemens Advia 2120i, Sysmex XE-5000, and Sysmex XN-2000
  22. Dacryocytes are a common morphologic feature of autoimmune and microangiopathic haemolytic anaemia
  23. Performance characteristics of a new automated method for measurement of anti-cyclic citrullinated peptide
  24. The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein I antibodies. A comparison with a homemade ELISA method
  25. Reference Values and Biological Variations
  26. Reference interval for immature platelet fraction on Sysmex XN hematology analyzer: a comparison study with Sysmex XE-2100
  27. Development of the first urinary reproductive hormone ranges referenced to independently determined ovulation day
  28. Cancer Diagnostics
  29. Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue
  30. Cardiovascular Diseases
  31. Elevated circulating levels of lipoprotein-associated phospholipase A2 in obese children
  32. Letters to the Editors
  33. Reporting of hemolysis index (HI) with laboratory results should be obligatory in newborns and infants
  34. Unmeasurably high chloride: a surrogate marker of thiocyanate poisoning identification
  35. Association between red cell distribution width and myocardial infarction in rheumatoid arthritis
  36. Plasmatic and urinary glycosaminoglycan profile in a patient affected by multiple sulfatase deficiency
  37. Rapid diagnosis of cryptococcal meningitis by Türk staining
  38. A high selectivity and sensitivity analytical method for the analysis of 8-hydroxy-2′-deoxyguanosine in the urine of Alzheimer’s disease patients
  39. S100B protein concentration measurement according to two different immunoassays
https://doi.org/10.1515/cclm-2014-1000
Keywords for this article
diagnostic validity; microRNAs; PCA3; prostate carcinoma; urine sediment

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Personalized medicine: moving from simple theory to daily practice
  4. Evaluating and using innovative technologies: a lesson from Theranos?
  5. Review
  6. Emerging biomarkers in the detection and prognosis of prostate cancer
  7. Mini Review
  8. Could molecular assessment of calcium metabolism be a useful tool to early screen patients at risk for pre-eclampsia complicated pregnancy? Proposal and rationale
  9. Opinion Papers
  10. Is laboratory medicine ready for the era of personalized medicine? A survey addressed to laboratory directors of hospitals/academic schools of medicine in Europe
  11. Theranos phenomenon: promises and fallacies
  12. Clinical laboratories: production industry or medical services?
  13. Genetics and Molecular Diagnostics
  14. Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms
  15. Direct identification of Gram-positive bacteria and resistance determinants from blood cultures using a microarray-based nucleic acid assay: in-depth analysis of microarray data for undetermined results
  16. General Clinical Chemistry and Laboratory Medicine
  17. Comparison between bottom-up and top-down approaches in the estimation of measurement uncertainty
  18. Role of vitamin D and sFlt-1/PlGF ratio in the development of early- and late-onset preeclampsia
  19. Adenosine deaminase, dipeptidyl peptidase-IV activities and lipid peroxidation are increased in the saliva of obese young adult
  20. PON-1 and ferroxidase activities in older patients with mild cognitive impairment, late onset Alzheimer’s disease or vascular dementia
  21. Comparison of five automated hematology analyzers in a university hospital setting: Abbott Cell-Dyn Sapphire, Beckman Coulter DxH 800, Siemens Advia 2120i, Sysmex XE-5000, and Sysmex XN-2000
  22. Dacryocytes are a common morphologic feature of autoimmune and microangiopathic haemolytic anaemia
  23. Performance characteristics of a new automated method for measurement of anti-cyclic citrullinated peptide
  24. The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein I antibodies. A comparison with a homemade ELISA method
  25. Reference Values and Biological Variations
  26. Reference interval for immature platelet fraction on Sysmex XN hematology analyzer: a comparison study with Sysmex XE-2100
  27. Development of the first urinary reproductive hormone ranges referenced to independently determined ovulation day
  28. Cancer Diagnostics
  29. Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue
  30. Cardiovascular Diseases
  31. Elevated circulating levels of lipoprotein-associated phospholipase A2 in obese children
  32. Letters to the Editors
  33. Reporting of hemolysis index (HI) with laboratory results should be obligatory in newborns and infants
  34. Unmeasurably high chloride: a surrogate marker of thiocyanate poisoning identification
  35. Association between red cell distribution width and myocardial infarction in rheumatoid arthritis
  36. Plasmatic and urinary glycosaminoglycan profile in a patient affected by multiple sulfatase deficiency
  37. Rapid diagnosis of cryptococcal meningitis by Türk staining
  38. A high selectivity and sensitivity analytical method for the analysis of 8-hydroxy-2′-deoxyguanosine in the urine of Alzheimer’s disease patients
  39. S100B protein concentration measurement according to two different immunoassays
Downloaded on 3.5.2026 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2014-1000/html?lang=en
Scroll to top button